Perrigo leveraged buyout
Executive Summary
Agreement between Perrigo management and parent company, Grow Group, to take the OTC private label manufacturer private again for $ 55.8 mil. has been terminated. Grow says it is "continuing discussions" with the Perrigo management group "concerning the possible sale of Grow's Perrigo subsidiary." The leveraged buyout agreement, announced March 24, had been scheduled for completion on March 31 ("The Pink Sheet" March 28, T&G-1).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.